Molecular Formula | C17H13Br2N5OS |
Molar Mass | 495.19 |
Density | 1.86±0.1 g/cm3(Predicted) |
Solubility | DMSO: ≥ 32 mg/mL |
Appearance | powder |
Color | white to brown |
pKa | 3.77±0.30(Predicted) |
Storage Condition | 2-8°C |
Stability | Stable for 1 year as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months. |
In vitro study | In human colorectal HCT116 and human fibrosarcoma HT1080 tumor cells, PTC-209 inhibited UTR-mediated reporter gene expression and BMI-1 endogenous. PTC-209 reduces the growth of rectal tumor cells in a BMI-1-dependent manner. In addition, PTC-209 damaged tumor-initiating cells by inhibition of irreversible growth. In human colorectal HCT116 and human fibrosarcoma HT1080 tumor cells, PTC-209 inhibited UTR-mediated reporter gene expression and BMI-1 endogenous. PTC-209 reduces the growth of rectal tumor cells in a BMI-1-dependent manner. In addition, PTC-209 damaged tumor-initiating cells by inhibition of irreversible growth. |
In vivo study | PTC-209 (60 mg/kg/day, s.c.) in mice xenografted with primary human colon cancer xenografts, human colon cancer cell lines LIM1215 or HCT116 can effectively inhibit the production of BMI-1 in tumor tissue, and stop the growth of tumor cells that have been generated. PTC-209 also reduces the frequency of functional colorectal cancer CICs in vivo. PTC-209 (60 mg/kg/day, S. C.) can effectively inhibit the production of BMI-1 in tumor tissue, and stop the growth of tumor cells that have been generated. PTC-209 also reduces the frequency of functional colorectal cancer CICs in vivo. |
Hazard Symbols | T - Toxic![]() |
Risk Codes | 25 - Toxic if swallowed |
Safety Description | 45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) |
UN IDs | UN 2811 6.1 / PGIII |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.019 ml | 10.097 ml | 20.194 ml |
5 mM | 0.404 ml | 2.019 ml | 4.039 ml |
10 mM | 0.202 ml | 1.01 ml | 2.019 ml |
5 mM | 0.04 ml | 0.202 ml | 0.404 ml |